Mydecine (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, was featured in a recent Bell2Bell Podcast episode in which its co-founder, chairman and CEO Josh Bartch shared the company’s goals for the new year. Of note was Mydecine’s phased approach, which entails understanding the imperfections of initial formulations and then improving aspects such as the nature of half-life, controllability delivery time, onset time, anxiety associated with different molecules, etc., in order to make them more effective. This approach has set the company apart from its peers. A recent article, which quotes Bartch, reads, “As a result, the first generation of products is already proving significantly better than what is currently available in the market. ‘For smoking cessation, for instance, you’re looking at no good solutions currently available in the market,’ noted Mr. Bartch. ‘You have Chantix, which was recently recalled for a cancer-causing carcinogen….’ With what Mydecine is offering, Bartch noted, early-stage trials have proven to be way better than what was available in the market. Efficacy has shown upwards of 80% in six months and 67% at 12 months, all attributed to the phased approach.”
To view the full article, visit https://ibn.fm/F7UAQ
About Mydecine Innovations Group Inc.
Mydecine is a biotechnology and digital technology company developing innovative first-and-second-generation novel therapeutics for the treatment of mental health and addiction through world-class technology and drug development infrastructure. Mydecine was founded in 2020 to address a significant unmet need and lack of innovation in the mental health and therapeutic treatment environments. The company’s global team is dedicated to efficiently developing innovative therapeutics to treat PTSD, depression, anxiety, addiction and other mental health disorders. Mydecine’s business model combines clinical trials and data outcome, technology, scientific and regulatory expertise with a focus on psychedelic therapy, as well as other novel molecules with differentiated therapeutic potential. By collaborating with some of the world’s foremost authorities, Mydecine aims to responsibly fast-track the development of new medicines to provide patients suffering from mental health disorders with safe and more effective treatment options. Mydecine Innovations Group is headquartered in Denver, Colorado, USA, with international offices in Leiden, Netherlands. For more information about the company, please visit www.Mydecine.com.
NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
